2003, Patients and Pharmaceutical research

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Patients

Pharmaceutical research

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Beating the Big C

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.

Side effects

Side effects Marketing Pharmaceutical Sales

Pharma Rep Focus

Paving the way for anti-Abeta active immunotherapy

Beating the Big C

Stay Connected